Board of Directors

Stephen Hoffman, M.D., Ph.D. (Chairman)

Stephen Hoffman M.D., Ph.D., is President of the consulting firm 10x Capital, Inc. and has been a Senior Advisor to PDL BioPharma, Inc. since February 2014. Prior to that he served as a Managing Director at Skyline Ventures, a venture capital firm, from 2007 to 2014 and was general partner at TVM Capital from 2003 to 2007. Prior to TVM, he served as President, Chief Executive Officer and a Director of Allos Therapeutics from 1994 to 2002, where he remained as Chairman until its acquisition by Spectrum Pharmaceuticals, Inc. in 2012. Allos in-licensed PDX from Memorial Sloan-Kettering Cancer Center, the Southern Research Institute and SRI International in 2002 and received U.S. Food and Drug Administration approval for Folotyn in 2009 for the treatment of the orphan disease peripheral T-cell lymphoma. Allos successfully launched and commercialized Folotyn in the U.S., and licensed it to Mundipharma for commercialization in ex-U.S. territories. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc. in 1998, where he held the position of Vice President of Science and Technology from 1987 until 1990. He currently serves on the board of directors of Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX), Genocea Biosciences, Inc. (NASDAQ: GNCA) and Hovione, Ltd.

Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology (1990 to 1994), both at the University of Colorado, and holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from the University of Colorado School of Medicine. He is also board-certified in Dermatology.    

 

Kevin Lee, Ph.D., MBA (CEO)

Kevin Lee, Ph.D., MBA, is Chief Executive Officer of Bicycle Therapeutics. Under his leadership, Bicycle Therapeutics’ strategy has become focused on developing novel treatments for oncology using Bicycle Drug Conjugates® to selectively deliver toxins to tumours. Dr. Lee joins Bicycle Therapeutics from Pfizer, where he served as Senior Vice President and Chief Scientific Officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programs across the full spectrum of research and development, established Pfizer’s Rare Disease strategy, conceptualized and implemented the company’s Gene Therapy strategy with the creation of the Genetic Medicine Institute and also founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GSK and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, Dr. Lee lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions.

Dr. Lee studied Pharmaceutical Sciences at Nottingham University followed by a Ph.D. in Pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research unit in Cambridge, U.K. Dr. Lee is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.

 

Kate Bingham, MBA (Director)

Kate Bingham joined SVLS in 1991. She currently serves or has served on the boards of companies in the U.K., U.S., Ireland, Sweden and Germany. She has been responsible for past investments in Alantos, Auxilium, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, Mednova, Micromet, PowderMed and RespiVert. Current investments include Autifony, Bicycle Therapeutics, Convergence and TopiVert.

Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge (U.S.) and at Monitor Company, a strategy consulting firm. She has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA.    

 

Deborah Harland, Ph.D., MBA (Director)

Deborah is a Partner at SR One, and joined in 2005 to establish the firm's European investment office. She brings to SR One extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during her more than 25-year tenure in the pharmaceutical industry. In addition to Bicycle Therapeutics, Deborah is currently a member of the Board of Directors of Atopix Therapeutics, Asceneuron, f-star, Mission Therapeutics and VH Squared. She was previously a member of the Board of Directors of Addex Pharmaceuticals (IPO, SIX Swiss Exchange, 2007), Pharmakodex Limited (sold to Orexo) and Syntaxin Limited (sold to Ipsen) and an observer on the Boards of Ablynx (IPO, Euronext Brussels 2007) and 7TM Pharma. Deborah received her BSc. (Hons.) in Pharmacology from the University of Bath, her PhD in Pharmacology from the University of London, and her MBA from Henley Management College.

 

Anja König, Ph.D. (Director)

Anja König, Ph.D. is a Managing Director at the Novartis Venture Fund in the Basel office. She is active in Europe and the U.S. She serves on the board of directors for Nabriva, Heptares, Covagen, F2G and Bicycle Therapeutics. Prior to joining Novartis, she was an Associate Partner at McKinsey and Company, a global consultancy, in New York City where she was a leader in McKinsey's North American Pharmaceutical Practice and a knowledge expert on pharmaceutical research and drug discovery. 

Dr. König is a scientist by training and holds a Ph.D. in Physics from Cornell University.    

 

Kazunori Maruyama, Ph.D. (Observer)

Kazunori Maruyama, Ph.D., is Executive Investment Director of Astellas Venture Management (AVM) since December 2015. Prior to the current position, Dr. Maruyama served as Director, Business Development/Innovation Management at Astellas Pharma from 2008 to 2015. He was one of the founding members of Yamanouchi Venture Capital (YVC, now a part of AVM), a corporate venture arm of Yamanouchi Pharmaceutical established in November 2000 and deeply contributed to expansion of its portfolio by nine investments from 2003-2007 at YVC/AVM, which resulted in four successful exits to date.  He joined the pharmaceutical industry as a research scientist at Yamanouchi Pharmaceutical in 1991, where he led a team of molecular endocrinology.

He holds a Ph.D. from The University of Tokyo.

 

Jason Rhodes, MBA (Director) 

Jason Rhodes is a Partner at Atlas Venture and focuses on the creation, development and business strategy of novel therapeutics companies. Prior to joining Atlas in 2014, Jason was President and Chief Financial Officer of Epizyme, Inc. (NASDAQ: EPZM), a public biopharmaceutical company. Prior to Epizyme, Jason was Vice President of Business Development at Alnylam (NASDAQ: ALNY). Prior to Alnylam, Jason was a founder and partner with Fidelity Biosciences, the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including Ironwood Pharmaceuticals (NASDAQ: IRWD), FoldRx (purchased by Pfizer) and Tetraphase (NASDAQ: TTPH). He holds a BA from Yale University and an MBA from the Wharton School of the University of Pennsylvania.

   

 

Sir Gregory Winter, FRS (Co-founder and Director)

Professor Sir Gregory Winter is a member of the Medical Research Council Laboratory of Molecular Biology (LMB) in Cambridge, U.K., and has served as both Deputy and Acting Director. He is a Fellow of the Royal Society, was knighted in 2004 for services to science and in 2012 was appointed by the Queen as Master of Trinity College, Cambridge.

He invented techniques to humanise rodent antibodies for use as therapeutics, and co-developed alemtuzumab/Campath-1H. Later, he developed methods to make fully human antibodies against human self-antigens using antibody libraries. His inventions are used in most of the antibody products on the market, including the humanised antibodies alemtuzumab/Campath-1H, trastuzumab/Herceptin, bevacizumab/Avastin, palivizumab/Synagis and the first human antibody (adalimumab/Humira) to be approved by the U.S. Food and Drug Administration.

Sir Gregory has acted as an entrepreneur to translate his scientific inventions to medicines. He was a founder of Cambridge Antibody Technology (CAT,1989) and Domantis (2000); these companies pioneered the use of antibody libraries to make fully human antibody therapeutics including adalimumab/Humira and belimumab/Benlysta.

Sir Gregory has won several international scientific prizes, including the Prix Louis Jeantet de Medecine (Switzerland) in 1989; the King Faisal International Prize for Medicine (Molecular Immunology, Saudi Arabia) in 1995; the Biochemical Analysis Prize of the German Society for Clinical Chemistry in 1995; the Cancer Research Institute William B. Coley Award (U.S.) in 1999; and the Royal Medal of the Royal Society in 2011. For his work with industry, he received the National Biotechnology Ventures Award (US) in 2004 and the BioIndustry Association Award (UK) in 2008. In March 2013 he was awarded the Gairdner Prize for the engineering of humanised monoclonal antibodies and their widespread use in medical therapy, particularly for treatment of cancer and immune disorders.

Sir Gregory is a graduate of University of Cambridge (1973), specialising in chemistry and biochemistry; for his PhD (1976) and postdoctoral work (1977-1981) he specialised in protein and nucleic acid sequencing, respectively, and with colleagues determined the genome sequence of influenza virus. From 1982 he pioneered the science of protein engineering, focusing first on enzymes (with A. Fersht) and then antibodies.